ArticleScientific reports2025
Enhanced therapeutic efficacy of Eupolyphaga sinensis Walker in females through sex-specific metabolomic-pharmacodynamic divergence.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Eupolyphaga sinensis Walker (ESW), a medicinal insect used in traditional Chinese medicine, is renowned for its effects on blood circulation, stasis resolution, and bone and tendon healing. The underlying reasons for the clinical preference for female ESW remain unclear. Previous investigations were limited in scope, focusing narrowly on female specimens, large-molecule compounds, and single pharmacological effect. This study systematically compared female and male ESW in terms of composition and therapeutic efficacy. Metabolomics identified 31 compound types in both female and male ESW, including lipids, amino acids, and fatty acids. Female ESW exhibited significantly higher levels of 8 bioactive compounds, 15 small peptides, and 13 prostaglandins compared to male ESW, which contribute to immunity enhancement, antithrombotic effects, and improved bone metabolism. These differences may underlie the superior medicinal efficacy of female ESW. In the thrombosis model, ESW can cause vasodilation, reduce blood cell aggregation and thrombosis rate of mice tails. It also improved t-PA levels, prolonged APTT, and enhanced hepatic SOD activity, with female ESW showing stronger effects on MDA and D2D levels, indicating its stronger ability to protect cells from damage and fibrinolytic effect. In the osteoporosis model, ESW increased femur length, liver, and thymus indices while regulating serum BALP and Mg levels. Female ESW notably reduced TRACP-5b, OT/BGP, P, and Cu to normal levels, indicating its stronger ability to improved bone metabolism, corrected disturbances in calcium-phosphorus metabolism, and regulated serum inorganic elements. Overall, female ESW exhibited a greater abundance of bioactive components and demonstrated superior anti-thrombotic and anti-osteoporotic effects. These findings highlight the superior therapeutic effects of female ESW due to its enriched bioactive components, supporting its clinical preference while underscoring the potential of male ESW for uilization of resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.